Publicacións en colaboración con investigadores/as de Hospital Ramón y Cajal (27)

2024

  1. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

    The Lancet Oncology, Vol. 25, Núm. 1, pp. 46-61

  2. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

    The Lancet Oncology, Vol. 25, Núm. 1, pp. 29-45

  3. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study

    Clinical and Translational Oncology

  4. Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer

    Cancers, Vol. 16, Núm. 14

  5. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

    European urology oncology, Vol. 7, Núm. 3, pp. 447-455

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

  2. Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

    European Urology Open Science

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

  2. Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer

    Cancers, Vol. 14, Núm. 2

2021

  1. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891

2020

  1. Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer

    European Urology

2019

  1. Collecting Duct Carcinoma of the Kidney: Analysis of Our Experience at the Spanish 'Grupo Centro' of Genitourinary Tumors

    Kidney Cancer, Vol. 3, Núm. 3, pp. 177-182

  2. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial

    Cancer, Vol. 125, Núm. 8, pp. 1301-1312

  3. Real-world outcome of 173 metastatic non-clear cell renal cell carcinoma (nccrcc) cases: The experience of the center group for genitourinary tumors

    Kidney Cancer, Vol. 3, Núm. 1, pp. 41-50

2018

  1. Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286

2017

  1. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study

    Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9

  2. Docetaxel in prostate cancer: A familiar face as the new standard in a hormone-sensitive setting

    Therapeutic Advances in Medical Oncology, Vol. 9, Núm. 5, pp. 307-318

  3. Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 341-356

  4. Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions (Clin Transl Oncol, 10.1007/s12094-016-1535-8)

    Clinical and Translational Oncology

  5. Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists

    Clinical and Translational Oncology, Vol. 19, Núm. 4, pp. 508-518